Glycominds Ltd. holds knowledge and experience in the field of glycomics, utilized for the discovery and development of glycan biomarkers which enable high-value medical diagnostics. Glycominds is developing and commercializing a new class of blood tests which allow physicians to detect cancer earlier, predict autoimmune disease progression and decide on therapy regimen.

Daktari Diagnostics develops products that deliver critical diagnostic information to clinicians and patients. Daktari's initial product is a handheld CD4 cell counter that aims to enable CD4 counting to be done by anyone. The company intends to bring this blood test to parts of the world where millions of people now have access to life-saving drugs, yet cannot begin treatment due to inadequate diagnostics.

Maroon Biotech is developing polymeric surfactants for cell membrane sealing and protein chaperoning. Applications for these developments are in wound healing, disease treatment, and industrial and food protein processing.

Zo­ray Technologies Inc. is developing a multiplex immunoassay platform for life science research and clinical diagnostics. Immunoassays that identify the presence of specific protein biomarkers in blood, urine, or saliva constitute a vital tool in modern healthcare. Zo­ray's technology aims to enable many immunoassays to be multiplexed on to one small disposable chip. While multiplexed immunoassays are emerging in life science research, existing techniques require a labeling step that adds variability, inhibit high density arrays, and provide a less quantifiable signal. With simple, inexpensive, label-free protein array detection, Zo­ray expects to make a strong impact in molecular in vitro diagnostics with tests that aim to provide more information than is currently feasible.

MND Diagnostics is a healthcare company focused on disease diagnosis. The medical device company has developed a diagnostic detection platform which aims to be rapid, low-priced and portable.

CS-Keys, LLC is creating cancer-specific biomarkers using advanced protein chemistry technologies (proteomics). The company is developing a new series of diagnostics to detect the occurrence or re-occurrence of cancer leading to more effective individualized treatment strategies for primary and metastatic disease, with an initial focus on breast cancer.